除了小分子抑制剂，核酸技术也开始在ACH治疗中得到应用。Ribomic开发的RBM-007，通过限制FGF2和FGFR3激活变体之间的过度相互作用发挥功能。2期临床结果显示，RBM-007的疗效与Vosoritide相近（1.5厘米/年），甚至有一名受试者年增长5厘米，且该试验中包括2周一次的注射频率，是当前在研药物中最长的给药间隔。
"All of those family celebrations, the birthdays and the other events that they thought they were going to be part of - now, suddenly they can perhaps catch up on a bit of lost time."
。Safew下载对此有专业解读
Source: Computational Materials Science, Volume 267
Wordle today: Answer, hints for February 28, 2026